Zusammenfassung
Der Arzneimittelstoffwechsel des Menschen weist eine erhebliche inter-individuelle Variabilität auf, wobei neben äußeren Faktoren auch genetisch determinierte Unterschiede in den metabolisierenden Enzymsystemen eine wesentliche Rolle spielen. Die Metabolisierungskapazität von Studienteilnehmern hinsichtlich den drei, bisher beschriebenen und am weitreichensten charakterisierten, genetischen Polymorphismen des Arzneimittelabbaus, dem Spartein/Debrisoquin-, dem Mephenytoin- und dem Acetylierungs-Polymorphismus, kann durch eine “Phänotypisierung” erfaßt werden.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
Literatur
Vesell ES and Penno MB, Assessment of methods to identify sources of interindividual pharmacokinetic variation. Clin Pharmacokinet 8, 378–409 (1983)
Breimer DD, Potential clinical relevance of the interplay between genetic and environmental factors. European Consensus Conference on Pharmacogenetics, COST B1, 69–81, Publ by Commission of the European communities (1990)
Schellens JHM and Breimer DD, Variability in drug metabolism: importance of genetic constitutions. Pharmac. Weekblad 9, 85–90 (1987)
Nerbert DW and Gonzalez FJ, P-450 genes: Structure, evolution and regulation. AnnRevBiochem 56, 45–993 (1987)
Guengerich FP, Polymorphism of cytochrome P-450 in humans. TIPS, 10, 107–109 (1989)
Breimer DD, Schellens JHM, Soons PA, Assessment of in vivo oxidative drug metabolizing enzyme activity in man by applying a “coktail” approach, In Microsomes and Drug Oxidations, eds Miners, JO Birkett, Drew DJ et al, 232–240, London: Taylor and Francis
Eichelbaum M, Reetz KP, Schmidt EK, Zekorn C, The genetic polymorphism of sparteine metabolism. Xenobiotica 16, 465–481 (1986)
Harrison PM, Tonkin AM, Dioxin ST and McLean AJ, Determination of debrisoquine and its 4-hydroxy metabolite in urine by high-performance liquid chromatography. J Chromat 374, 204–208 (1986)
Park YH, Kullberg MP and Hinsvark ON, Quantitative determination of dextrometorphan and three metabolites in urine by reverse-phase high-performance liquid chromatography. J Pharmac Sci 73 (1), 24–29 (1984)
Wilkinson GR, Guengerich FP and Branch RA, Genetic polymorphism of S-mephenytoin hydroxylation. Pharmac Therap 42, 53–76 (1989)
Wedlund PJ, Aslanian WS, Jacqz E, McAllister CB, Branch RA and Wilkinson GR, Phenotypic differences in mephenytoin pharmacokinetics in normal subjects. J Pharmacol Exp Ther 234, 662–669 (1985)
Price Evans DA, N-Acetyltransferase. Pharmac Therp 42, 157–343 (1989)
Kilbane AJ, Silbart LK, Manis M, Beitins IZ and Wendell WW, Human N-acetylation genotype determination with urinary caffeine metabolites. ClinPharmacolTher 47, 470–477 (1990)
Eichelbaum M. and Gross AS, The genetic polymorphism of debrisoquine/sparteine metabolism. — Clinical aspects Pharmac Therap 46, 377–394 (1990)
Eichelbaum M, Zur Problematik genetischer Polymorphismen im oxidativen Arzneistoffwechsel des Menschen. In: Toxikologische und klinische-pharmakologische Prüfungen, Hsg Grosdanoff P, Kraupp O et al, Verlag Walter de Gryter, 555–565 (1990)
Balant LP, Gundert-Remy U, Boobis AR and von Bahr C, Relevance of genetic polymorphism in drug metabolism in the development of new drugs. EurJClinPharmacol 36, 551–554 (1989)
Brosen K, Recent developments in hepatic drug oxidation- Implications for clinical pharmacokinetics.Clin Pharmacokinet 18 (3), 220–239 (1990)
Lennard MS, Tucker GT and Woods HF, Inborn ‘errors’ of drug metabolism. Pharmacokinetic and Clinical Implications. Clin Pharamcokinet 19 (4), 257–263 (1990)
Speirs CJ, Murray S, Boobis AR, Seddon CE, Davies DS, Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metaboliseres of debrisoquine. BrJClinPharmacol 22, 739–743 (1986)
Brosen K and Gram LF, Clinical significance of the sparteine/debrisoquine oxidation polymorphism. EurJClin Pharmacol 36, 537–547 (1989)
Gram LF, Overo KF, Drug Interaction: Inhibitory effect of neuroleptics on metabolism of tricyclic antidepressants in man. Br Med J 1, 463–465 (1972)
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1993 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Unseld, E. (1993). Phänotypisierung — Relevanz des genetischen Polymorphismus im Arzneimittelstoffwechsel. In: Lange, L., Seifert, W., Jaeger, H., Klingmann, I. (eds) Pharmakodynamische Modelle für die Arzneimittelentwicklung. Konzepte in der Humanpharmakologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-50229-3_5
Download citation
DOI: https://doi.org/10.1007/978-3-642-50229-3_5
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-50230-9
Online ISBN: 978-3-642-50229-3
eBook Packages: Springer Book Archive